Skip to content
LATEST
Health

CPL500036 Phase 2 trial reaches completed status

The study compared low and high doses with placebo while assessing safety, efficacy and pharmacokinetics in levodopa-induced dyskinesia.

CPL500036 Phase 2 trial reaches completed status

CPL500036's Phase 2 study in levodopa-induced dyskinesia was listed as completed in a ClinicalTrials.gov registry record published Nov. 12.

The mid-stage human trial matters because it moves Celon Pharma SA's drug candidate past a designed test of safety, efficacy and pharmacokinetics, compared with placebo and two dose levels.

The registry identifies three study arms: low-dose CPL500036, high-dose CPL500036 and placebo. Pharmacokinetics refers to how a drug moves through the body, including absorption and clearance.

Celon Pharma SA and the National Center for Research and Development, Poland, are listed as sponsors of the study. Levodopa-induced dyskinesia is an involuntary movement complication associated with levodopa treatment in Parkinson disease.

Completion of a Phase 2 trial does not, by itself, show that a drug is effective or safe enough for approval.

Investors, clinicians and patients tracking Parkinson-related movement-disorder treatments will need the reported efficacy and safety data before judging whether CPL500036 can proceed further in clinical development.

Source: clinical registry, ClinicalTrials.gov, Nov. 12

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news